{
    "paper_id": "3a842c580be37fa54056b92ee7c93505c55a912e",
    "metadata": {
        "title": "",
        "authors": []
    },
    "abstract": [],
    "body_text": [
        {
            "text": "antimicrobial spectrum, routes of administration and dosages, 1206t-1207t dosage in renal failure, 1213t-1214t pharmacokinetics of, 1205t susceptibilities of selected bacteria to, 1208t-1209t Cefadroxil antimicrobial spectrum, routes of administration and dosages, 1206t-1207t dosage in renal failure, 1213t-1214t pharmacokinetics of, 1205t susceptibilities of selected bacteria to, 1208t-1209t Cefamandole, prophylaxis, 1158t Cefazolin for anaerobic infection, 1634 antimicrobial spectrum, routes of administration and dosages, 1206t-1207t for catheter-related bloodstream infection (CRBSI), 436t for cellulitis, 92 for complicated urinary tract infection, 545t dosage in renal failure, 1213t-1214t for endophthalmitis, 163t for infective arthritis, 386t for lung abscess, 269f neurologic effects of, 1215 pharmacokinetics of, 1205t prophylaxis, 1158t susceptibilities of selected bacteria to, 1208t-1209t Cefdinir antimicrobial spectrum, routes of administration and dosages, 1206t-1207t dosage in renal failure, 1213t-1214t otitis media and, 238t pharmacokinetics of, 1205t susceptibilities of selected bacteria to, 1208t-1209t Cefditoren antimicrobial spectrum, routes of administration and dosages, 1206t-1207t dosage in renal failure, 1213t-1214t pharmacokinetics of, 1205t susceptibilities of selected bacteria to, 1208t-1209t Cefepime antimicrobial spectrum, routes of administration and dosages, 1206t-1207t for complicated urinary tract infection, 545t dosage in renal failure, 1213t-1214t for hospital-acquired pneumonia, 260t indication, brain abscess, 202-203 for lung abscess, 269f for P. aeruginosa infection, 1210 pharmacokinetics of, 1205t susceptibilities of selected bacteria to, 1208t-1209t Cefixime antimicrobial spectrum, routes of administration and dosages, 1206t-1207t for complicated urinary tract infection, 544t dosage in renal failure, 1213t-1214t for enteric fevers, 1006 for gonorrhea, 595 pharmacokinetics of, 1205t susceptibilities of selected bacteria to, 1208t-1209t Cefmetazole, for anaerobic bacteria, 1643 Cefoperazone antimicrobial spectrum, routes of administration and dosages, 1206t-1207t dosage in renal failure, 1213t-1214t for P. aeruginosa infection, 1210 pharmacokinetics of, 1204, 1205t susceptibilities of selected bacteria to, 1208t-1209t Cefotaxime antimicrobial spectrum, routes of administration and dosages, 1206t-1207t for complicated urinary tract infection, 545t dosage in renal failure, 1213t-1214t for epiglottitis, 233 for leptospirosis, 1103 in liver transplant patients, 754t for lung abscess, 269f for meningitis, 180 pharmacokinetics of, 1205t prophylaxis, 1158t susceptibilities of selected bacteria to, 1208t-1209t Cefotetan for anaerobic bacteria, 1634, 1643 antimicrobial spectrum, routes of administration and dosages, 1206t-1207t dosage in renal failure, 1213t-1214t indications, lung abscess, 269f pharmacokinetics of, 1204, 1205t susceptibilities of selected bacteria to, 1208t-1209t Cefoxitin for anaerobic bacteria, 1634, 1643 antimicrobial spectrum, routes of administration and dosages, 1206t-1207t for dog bites, 657t dosage in renal failure, 1213t-1214t for foot ulcers, 131t for lung abscess, 269f pharmacokinetics of, 1205t susceptibilities of selected bacteria to, 1208t-1209t Cefpodoxime indication, otitis media, 238t indications, lung abscess, 269f susceptibilities of selected bacteria to, 1208t-1209t Cefpodoxime proxetil antimicrobial spectrum, routes of administration and dosages, 1206t-1207t for complicated urinary tract infection, 544t for cystitis, 528t dosage in renal failure, 1213t-1214t pharmacokinetics of, 1205t Cefprozil antimicrobial spectrum, routes of administration and dosages, 1206t-1207t dosage in renal failure, 1213t-1214t pharmacokinetics of, 1205t susceptibilities of selected bacteria to, 1208t-1209t Ceftaroline antimicrobial spectrum, routes of administration and dosages, 1206t-1207t for complicated urinary tract infection, 545t dosage in renal failure, 1213t-1214t for lung abscess, 269f pharmacokinetics of, 1205t susceptibilities of selected bacteria to, 1208t-1209t Ceftazidime antimicrobial spectrum, routes of administration and dosages, 1206t-1207t for brain abscess, 202-203 for cancer patients, 734-735 for catheter-related bloodstream infection (CRBSI), 436t for complicated urinary tract infection, 545t dosage in renal failure, 1213t-1214t for drowning-associated infections, 681 for endophthalmitis, 162 for hospital-acquired pneumonia, 260t for lung abscess, 269f for melioidosis, 1077t for P. aeruginosa infection, 1210 pharmacokinetics of, 1205t susceptibilities of selected bacteria to, 1208t-1209t Ceftazidime-avibactim, for complicated urinary tract infection, 545t Ceftibuten antimicrobial spectrum, routes of administration and dosages, 1206t-1207t for complicated urinary tract infection, 544t dosage in renal failure, 1213t-1214t pharmacokinetics of, 1205t susceptibilities of selected bacteria to, 1208t-1209t Ceftizoxime antimicrobial spectrum, routes of administration and dosages, 1206t-1207t dosage in renal failure, 1213t-1214t for lung abscess, 269f pharmacokinetics of, 1205t susceptibilities of selected bacteria to, 1208t-1209t Ceftobiprole antimicrobial spectrum, routes of administration and dosages, 1206t-1207t dosage in renal failure, 1213t-1214t for P. aeruginosa infection, 1210 pharmacokinetics of, 1205t susceptibilities of selected bacteria to, 1208t-1209t Ceftolozane-tazobactam antimicrobial spectrum, routes of administration and dosages, 1206t-1207t dosage in renal failure, 1213t-1214t for P. aeruginosa infection, 1210 pharmacokinetics of, 1205t susceptibilities of selected bacteria to, 1208t-1209t Ceftriaxone antimicrobial spectrum, routes of administration and dosages, 1206t-1207t for cancer patients, 734-735 for cellulitis, 92 chemoprophylaxis, for meningococcal disease, 1560 for community-acquired pneumonia, 255t for complicated urinary tract infection, 545t dosage in renal failure, 1213t-1214t for enteric fevers, 1006 for epididymitis and orchitis, 538 for epiglottitis, 233 for foot ulcers, 131t for gonorrhea, 595 for Haemophilus ducreyi, 1621 for hospital-acquired pneumonia, 260t for infective arthritis, 386t for lung abscess, 269f for Lyme disease, 412 for meningitis, 187t for otitis media, 238t in outpatient parenteral antimicrobial therapy, 1201 pharmacokinetics of, 1204, 1205t susceptibilities of selected bacteria to, 1208t-1209t for syphilis, 565 , 195-197, 195t, 196f enteroviruses and, 1411 epidemiology of, 189, 190f, 191t 190-194, 195f definition of, 189 diagnosis of, 195-197, 195t, 196f epidemiology of, 189, 190f, 191t ",
            "cite_spans": [
                {
                    "start": 6439,
                    "end": 6517,
                    "text": ", 195-197, 195t, 196f enteroviruses and, 1411 epidemiology of, 189, 190f, 191t",
                    "ref_id": null
                },
                {
                    "start": 6518,
                    "end": 6617,
                    "text": "190-194, 195f definition of, 189 diagnosis of, 195-197, 195t, 196f epidemiology of, 189, 190f, 191t",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": ""
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "HIV/AIDS",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Xerosis",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "879--880",
            "other_ids": {}
        }
    },
    "ref_entries": {
        "TABREF0": {
            "text": "CD8 cells, mycobacteria and, 1649-1650 CD8 lymphocytes, in rheumatic fever, 471-472 CD8 + T-cell, cellular immune responses, 33 CD8 T-cell, response to HIV-1 of, 841",
            "latex": null,
            "type": "table"
        },
        "TABREF2": {
            "text": "for parasitic infections, 1345t-1351t pharmacodynamics of, 1335 pharmacokinetics and distribution of, 1335 route of administration, 1335 for systemic candidiasis, 1686 for Talaromyces marneffei, 1699 5-Flucytosine, for fungal urinary tract infection, 545t Fludarabine, 725 Fluid administration, for dengue, 1122 Fluid imbalances, in severe malaria, 1020t Fluid replacement, for cholera, 1607 Flukes. see Trematodes. market withdrawal of, 1239, 1239t mode of action of, 1174, 1176f pediatric use of, 1246 for pertussis, 1614 pharmacodynamics of, 1174-1175 for plague, 1083-1084 prophylaxis with, in cancer patients, 731f, 736 for prostatitis, 535-536, 535t-537t for Pseudomonas aeruginosa, 1589 for pyelonephritis, 552 resistance to, 1174, 1186 mycobacterial, 1656t for Rhodococcus equi, 1551 for Stenotrophomonas maltophilia, 1597 for travelers' diarrhea, 376, 950 for tularemia, 1617 for typhoid fever, 1005-1006 see also individual drugs Fluorouracil, chemical structure of, 1335f Flurithromycin characteristics of, 1218t classification, 1217 pharmacokinetics of, 1223t Focal lesions, in Chagas disease, 1070 Focal neurologic abnormalities, 183-184 Focal pyogenic infections of the central nervous system, Diabetic foot, ulcers Forced expiratory volume of air in 1 second (FEV 1 ), 247 Fordyce spots, 586t-587t Forestry worker, and occupational infections, 648t-649t Fusarium oxysporum, 1699 Fusarium solani, 1699 fusB gene, 1193 fusC gene, 1193 Fusidic acid, 1169, 1277-1278 adverse reactions and interactions of, 1277-1278, 1278t chemical structure of, 1169 dosage of, 1277 indications of, 1277 mechanism of action, 1277 mechanisms of resistance, 1277 mode of action of, 1169 pharmacodynamics of, 1169 pharmacokinetics of, 1277 resistance to, 1169, 1193 route of administration, 1277 spectrum of activity, 1277 for Staphylococcus aureus, 1521 Fusin. see CXCR4. Gas-liquid chromatography, for anaerobic bacteria, 1635 Gastric adenocarcinoma, 321-322 and Helicobacter pylori, 21 pathogenesis and pathology of, 324 Gastric carcinoma, from Helicobacter pylori, 1604 Gastrointestinal adverse reactions, of folate inhibitors, 1283 Gastrointestinal anthrax, 1125-1126 Gastrointestinal bleeding, typhoid fever and, 1004 Gastrointestinal cytomegalovirus disease, 852 Gastrointestinal disease, probiotics for, 1373-1375, 1375f Gastrointestinal effects, \u03b2-lactam antibiotics, 1215t, 1216 989t, 991-994, 996-997, 1000-1001, 1001t host susceptibility and, 990 human factors in, 990 management of, 997-1001 pathogenesis and pathology of, 990-994 prevention of, 994-995 protozoa, 989t, 990-991, 995, 997-1000, 1000t see also specific parasites Gastrointestinal problems, in immunologically mediated diseases, 773, 773f Gastrointestinal reactions, of quinolones, 1247 Gastrointestinal source, brain abscess and, 199 Gastrointestinal surgery, antibiotic prophylaxis and, normal flora, 12, 1631-1632, 1632t parasitic infections of. see Gastrointestinal parasites role of, in HIV-1 infection, 840-841, 841f Gastrointestinal tuberculosis, 341-343 Gatifloxacin dissociation constants of, 535t for enteric fevers, 1006 for prostatitis, 536t Gel diffusion, for helminths diagnosis, 1777 Gemella haemolysans, 156 Gemella morbiliform, in human bites, 683t Gemella morbillorum, 1631 Gene cassettes, 1195-1196, 1196f resistance and mechanism of resistance for, 1196t Genomic DNA, for Pseudomonas aeruginosa, 1583t-1584t Genomics, advances in, 1388-1389 GenoType kits, 1654 Genotypes, hepatitis B virus, 364, 365f Genotypic analyses, for herpesvirus, 1435 Genotypic tests, of HIV-1 drug resistance, 1489 Genotypic typing method, for Acinetobacter baumannii, Corticosteroids Glucose, malaria in pregnancy, 1143t-1144t Glutamate dehydrogenase (GDH) antigen, 1630 Glycocalyx, 15 Glycopeptide-intermediate Staph. aureus (GISA), 1192 Glycopeptides, 1164-1167, 1249-1255 Graded exercise therapy (GET), 635 Graft-versus-host disease (GVHD), 713 and hematopoietic stem cell transplantation, 739-741 Gram-negative bacilli, 1579-1599, 1628t, 1631 antibiotic therapy for, 1579-1580 catheter-related bloodstream infection (CRBSI), 427, 435 drug-resistant, 1210 endophthalmitis and, 160 epidemiology of, 1579 hospital-acquired pneumonia and, 259t infection sites of, 1629t lung abscess and, 263-264 macrolides, 1219 nomenclature of, 1581t-1582t nonfermenting, 1597-1599 nosocomial infections due to, 1588t pathogenic role of, 1579, 1579t in pericarditis, 450 in recurrent cellulitis, 134 urinary tract infection with, 527t Head and neck surgery antibiotic prophylaxis and, 1157t-1158t, 1158 infections after, anaerobic bacteria in, 1637 Health, occupational and employee, 57 Health beliefs models, and HIV transmission, 826 Health care, impact of HIV and AIDS on, in low-and middle-income countries, 895 Health-care associated pneumonia (HCAP), 258-262 Health consequences of changing climate, 40-48 Healthcare-associated infections (HAIs), 54, 60 lactamase-mediated, 1181-1184 mediated by altered PBPs, 1184 mediated by impermeability or efflux, 1184-1185 route of administration and dosage, 1206 spectrum of activity, generic names, routes of administration and dosages, 1206t-1207t for Staphylococcus aureus, 1520 susceptibilities of selected bacteria to, 1208t-1209t for tularemia, 1089 in urinary tract infections, 763 see also specific drugs \u03b2-lactamase inhibitors, anaerobic bacteria and, 1643",
            "latex": null,
            "type": "table"
        },
        "TABREF3": {
            "text": "Salpingitis, from Neisseria gonorrhoeae, 1562-1563 Salt-and-pepper fundus, 168f Sand flies, 106t, 111, 1673, 1756 arboviruses, 1493, 1495t infections from, 191t leishmaniasis and, 1059 Sand fly fever Naples, 1495t Sand fly fever Sicilian, 1495t Sanger sequencing, 63, 63t Sanitation, for prevention of food-borne diarrheal illness, 334 SAPHO syndrome, 393 Sapovirus, 1393-1396 clinical characteristics of, 1391t clinical manifestations of, 1396 diarrhea and, 335, 338 epidemiological characteristics of, 1391t epidemiology of, 1394 structure and morphological characteristics of, 1391f, 1391t taxonomy of, 1394t Sappinia, 1744 Sappinia diploidea nature of, 1744 treatment of, 1345t-1351t Saquinavir, 1148t, 1303 effect on oral contraceptives, 907t perinatal HIV transmission prevention, 909t Sarcocystis hominis, 1734 Sarcocystis nesbitti, 1734 Sarcocystis suihominis, 1734 Sarcoidosis, 626 in HIV patients receiving antiretroviral therapy, 864 lymphadenopathy and, 137t-138t Sarcoptes scabiei from cats, 660 from dogs, 658-659 SARS. see Severe acute respiratory syndrome (SARS). 1029f diagnosis of, 1030-1031 epidemiology of, 1026-1028, 1027f female genital, 1030 geographic distribution of, 939, 941f intestinal/hepatic, 1029-1030 life cycle of, 1026f management of, 1031 neurologic, 1030 pathogenesis and pathology of, 1028, 1028f prevention of, 1028-1029, 1028f transmission of, 1031 treatment of, 1345t-1351t urinary, 1029, 1029f Schistosomiasis Control Initiative (SCI), 1029 Schnitzler's syndrome, 614 Sclerosing keratitis, 981 Sclerosing lymphangitis, 586t-587t Scombroid poisoning, 331, 332f Scopulariopsis brevicaulis, 122-123 Scrapie, 215t epidemiology of, 214-215 pathology, 219-220 Scratches, treatment of, 1462 Screening, as prevention modality, in HIV, 826 Scrofuloderma, 117, 117f Scrotum inflammation, in filariasis, 1049 Scrub typhus, 644, 1091-1097, 1670-1671 Scytalidium dimidiatum, clinical features of, 126, 127f Sea bathing, and recreational infections, 645 Seafood, in non-infective food poisoning, 331 Seal finger, 668 Seasonal influenza, 1470 abdominal. see Intra-abdominal sepsis laboratory-based diagnostics in, 419-420 mortality in, 416 organ dysfunction and, 424 pathogen recognition systems in, 421, 422f, 422t pathogens in, identification of, 420 pathophysiology of, 420-424, 422t perspectives in, 426 plague and, 1081 postabortion, 496 prevention of, 424 pro-inflammatory mediators in, 422-423 risk factors for, 416-419, 416b source of, 420 therapy for, 424-426 vascular endothelium and, malfunction of, 423-424 virulence factors in, 419, 419f-420f, 419t Sepsis-like illness, 509 Seroconversion, for Leptospira spp., 1609 Severe malaria, clinical cases, 1141-1142 Sewage worker, and occupational infections, 648t-649t Sex, and endemic treponematoses, 961 Sex partners, management of, 601 Sexual intercourse, in pregnancy, 502 Sexually acquired reactive arthritis, Mycoplasma genitalium Sheep liver fluke, treatment of, 1345t-1351t Shewanella, 1581t-1582t, 1599 Shiga toxin, 330 Shiga-toxin Escherichia coli antibiotic therapy of, 334 doses of, in diarrheal illness, 329t see Septic shock in severe malaria, 1021, 1025 see also Toxic shock syndrome (TSS) Shotgun metagenomic sequence, 70-71, 70f-71f SHV-1, 1183 Siberian tick typhus, 1667t, 1668 Sickle cell anemia clinical features of, 1056 pathogenesis and pathology of, 1053-1054 Sickness Impact Profile (SIP-8), 631-632 Signal regulatory proteins (SIRP's), 31-32 Silicone breast implant, lymphadenopathy, 137t-138t Silver nitrate eye drops, 151 Simeprevir (SMV), for hepatitis C, 1331 Simian immunodeficiency virus (SIV), 666, 839 pathogenesis and pathology, 846 studies in, 846 Simkania, 1221 Simulium damnosum, 1765 Sin Nombre virus (SNV), 12, 1110, 1502, 1503t Sindbis virus, in infective arthritis, 387t Sine qua non, in wound evaluation, in burns, 699 Single cell genome sequencing, 63 Single nucleotide polymorphisms (SNPs), 65 Single photon emission CT (SPECT), brain abscess and, Skin damage, onchocerciasis and, 1049 Skin disease, nontuberculous mycobacteria (NTM), localized, 287 Skin infections, 85t anaerobic bacteria in, 1632f, 1638t, 1639-1640, 1639f-1640f antimicrobial therapy for, 1641t blastomycosis in, 1703 in cancer patients, 727, 727f candidosis in, 1710 cryptococcosis in, 1695 differential diagnosis of, 85t from groups A, C and G streptococci, 1532 in HIV/AIDS, 858 immunologically mediated diseases, 773-774, 774f Volume 1: pp 1-811 \u2022 Volume 2: pp 812-1780 linezolid, 1231, 1231t in melioidosis, 1075 mucormycosis in, 1698 Mycoplasma pneumoniae in, 1661 nomenclature of, 85t Pseudomonas aeruginosa in, 1582, 1587t, 1588, 1588f, Skunks, infections from, 191t 'Slapped cheek,' in parvovirus infection, 1451, 1451f Slaughterer, and occupational infections, 648t-649t Slide coagulase test, for staphylococci, 1517f Slime-associated antigen (SAA), 1516 Slit skin smears, for leishmaniasis, 1063, 1063f Slugs, infections from, 191t Small intestinal bacterial overgrowth (SIBO), 346 Small mammal pets, diseases associated with, 657t, 661 Small multidrug resistance (SMR), 1194f Smallpox and bioterrorism, 671t-673t, 675-677 clinical features of, 676, 676f differential diagnosis of, 676 rash of, 676, 677f transmission of, 676-677 dermatologic manifestations of, 114t-115t immunization for, and occupational infections, 650t-651t Smear microscopy, for laboratory diagnosis, of mycobacteria, 1652 Smoke inhalation injury, and pneumonia, 698 Snails infections from, 191t in schistosomiasis, 1026 'Snowflake' keratitis, 981 Social cognitive models, and HIV transmission, 826 Sodium absorption, 335-336 Sodium stibogluconate, for parasitic infections, 1345t-1362t, 1369 Sofosbuvir (SOF), for hepatitis C, 1331 Soft chancre, 589 Soft ticks, 104-105 Soft tissue, deep, 95 Soft tissue infections aerobic actinomycetes and, 1551 anaerobic bacteria in, 1632f, 1638t, 1639-1640, 1639f-1640f antimicrobial therapy for, 1641t in cancer patients, 727, 729f clinical features, diagnosis and management of, 86-93 etiology of, 85t immunologically mediated diseases, 773-774, 774f linezolid, 1231, 1231t in melioidosis, 1075, 1076f Pseudomonas aeruginosa in, 1587t, 1588, 1588f, 1593f quinolones for, 1245 see also Skin infections; Subcutaneous infections; specific infections Soil, infections from, 191t Solid organ transplant (SOT), 781 candidates of, vaccination follow-up of, 789t patients having, fever of unknown origin in, 615 recipients of, vaccinal follow-up of, 790t systematic approach to vaccinating patients with, 787 see also Organ transplantation; specific organs Sonication, in prosthetic joint infection (PJI), 401 Sore throat, streptococcal, 472 South American hemorrhagic fever, and bioterrorism, 671t South Asia, infections in, 1130 South East Asia, infections in, 1130 Southern tick-associated rash illness (STARI), 408 Spa baths, and recreational infections, 644-645 Spa typing, staphylococci and, 1519 'Spanish influenza' pandemic, 1466 Sparfloxacin, dissociation constants of, 535t Sparganosis, 1036, 1036f, 1766, 1772, 1778 from amphibians, 669 Specific granule deficiency, 705t Specimen collection in anaerobic bacteria, 1634-1635, 1634t for laboratory diagnosis, of mycobacteria, 1650-1652, 1651t for viral hemorrhagic fevers, 1116 see also Diagnostic microbiology; specific specimens Sphingobacterium, 1581t-1582t, 1599 Sphingomonas, 1581t-1582t Spinal cord, transverse myelitis and, 191 Spinal cord abscess, 207 Spinal cord injury, in complicated urinary tract infection, Spiramycin adipate, pharmacokinetics, 1224t Spiramycin I, characteristics of, 1218t Spirillum minus, rat-bite fever, 661 Spirochaetales, 1600, 1608-1609 Spirochetes, in myocarditis, 447 Spirometra, 1036, 1036f, 1772 Splanchnic bed, ischemia of, 686 Sporotrichosis schenckii, in skin manifestation of HIV, 884t Sports, and recreational infections, 645 Spotted fever group rickettsiae, 1091, 1666-1669 Squamous cell carcinoma, 577, 579, 581f, 586t-587t in skin manifestation of HIV, 884-885 Squamous cell carcinoma in situ, 586t-587t Squamous cells, 580-581, 580f Squamous intraepithelial lesion, 580f SSSS. see Staphylococcal scalded skin syndrome (SSSS). St Louis encephalitis, 1493f, 1495t St Louis encephalitis virus (SLE), encephalitis/myelitis caused by, 192t St Vitus' dance, 473, 1533 Standard non-treponemal (reaginic) tests, 563-564, 564t, 566 Staphopain A, 1513t-1514t Staphylococcal complement inhibitor (SCIN), 1513t-1514t Staphylococcal enterotoxin B, and bioterrorism, 671t Staphylococcal immunoglobulin-binding protein (SBI), 1513t-1514t Staphylococcal infection dermatologic manifestations of, 114t-115t lymphadenopathy and, 137t-138t Staphylococcal scalded skin syndrome (SSSS), 87-88, 88f, 116, 116f Staphylococcal superantigen-like 3, 1513t-1514t Staphylococcal superantigen-like 5 (SSL5), 1513t-1514t, 1514 Staphylococcal superantigen-like 7 (SSL7), 1513t-1514t Staphylococcal superantigen-like 10, 1513t-1514t acquired MRSA, 1511, 1511f nosocomial, 1509-1511 folliculitis and, 86-87 in foot ulcers, 130-131 furunculosis and, 87, 87f fusidic acid for, 1277 genetic location of, 1515 hospital-acquired pneumonia and, 259t in human bites, 682, 683t hydrocephalus shunts and, 221 immunostimulatory molecules of, 1515, 1515f impetigo and, 88 infective endocarditis, 748 inhibition of neutrophil recruitment and activation, 1514 interactions with the coagulation system, 1515 isolation and determination of, 1516-1517, 1516f-1517f lincosamides, 1224-1225 linezolid, 1230 lower respiratory tract infections, 264f, 1221 management of, 1520-1521, 1520t-1521t in mastitis, 501 methicillin-resistant. see Methicillin-resistant Staphylococcus aureus (MRSA) methicillin-susceptible. see Methicillin-susceptible Staphylococcus aureus (MSSA) multidrug-resistant gram-positive bacteria, 1289-1290 myocarditis and, 446-447 in osteomyelitis, 388-390, 389f, 394f, 395, 395t in otitis media, 236, 1637 pathogenicity of, 1512-1515 peritonitis and, 380-381 pneumonia in HIV/AIDS, 857 665t and tumor necrosis factor inhibitor, 797-799 vancomycin-resistant. see Vancomycin-resistant Staphylococcus aureus (VRSA) vancomycin susceptibility for, 1249, 1249t in vertebral osteomyelitis, 391-392 virulence factors of, 1513t-1514t, 1515 wound infections with, 1509 Staphylococcus hyicus, 1509 Staphylococcus intermedius, 1509 cellulitis and, 90 Staphylococcus saccharolyticus, 1631 Staphylococcus saprophyticus, in cystitis, 523 Staphylokinase (SAK), 1512, 1513t-1514t Staphylolysin, 1522 Staphyloxantin (golden pigment), 1513t-1514t in special circumstances, 1297t, 1298 drug interactions of, 1298 indication for, 1298 perinatal HIV transmission prevention, 909t pharmacokinetics and distribution of, 1298 resistance to, 1298 route of administration of, 1298 Stellate neuroretinitis, 168 Stem cell transplantation, 715 see also Hematopoietic stem cell transplantation Stenotrophomonas, nomenclature of, 1581t-1582t Stenotrophomonas maltophilia, 1596-1597 Stevens-Johnson syndrome, Mycoplasma pneumoniae in, 1661 Stillbirth, congenital infection and, 509 Still's disease, adult onset, and fever of unknown origin, Streptococcus agalactiae, meningitis and, 182t Streptococcus anginosus, 1532, 1631 in human bites, 683t pyogenic liver abscess, 361 Streptococcus constellatus, in human bites, 683t Streptococcus gallolyticus clinical manifestations of, 1534 management of, 1534-1535 Streptococcus iniae, 91 Streptococcus intermedius, in human bites, 683t molecular characterization and population structure of, 1525 opportunistic infection in HIV, 857 in osteomyelitis, 395t otitis media of, 236 pathogenesis of, 1531-1532, 1531f pneumonia in HIV/AIDS, 857 in postsplenectomy sepsis, 777, 778t prevention of, 1535 primary (spontaneous) peritonitis, 359 resistance to penicillin, 1184 to quinolones, 1186 respiratory tract infection, 1132 in sinusitis, 1637 in thoracic transplantation patients, 747t treatment, \u03b2-lactam antibiotics, 1209 see also Pneumococcal infections Infected-Recovered (SIR) model, 51, 52f Sutezolid, as antituberculosis agent, 1271 'Sweaty tennis shoe syndrome' , 91 Swimmer's itch, 87, 88f, 645, 1029 Swimming pools, and recreational infections, 645 Swine, infections from, 191t Swine erysipelas, 1542 Swine influenza (H1N1V) pandemic 2009, 1467-1468, 1468f Swineherd's disease, 664 Sycosis barbae, 86 Sydenham's chorea, 471, 473, 1533 Symmer's pipe-stem fibrosis, 1030 Symptomatic cystitis, treatment of, 443t Syndrome-based sampling, 1386, 1387f and skin manifestations of HIV, 884 tertiary gummatous, 562-563, 562f transmission of, 559 uveitis and, 168-169 Syphilis condylomata lata, 586t-587t Systemic antifungal agents, 1333-1344 Systemic candidiasis, 439-445, 1686-1687 Systemic disease, diphtheria and, 1546 Systemic fungi, 1700-1701, 1700t Systemic infections, dermatologic manifestations of, cell deficiency, brain abscess and, 199 T-cell depletion (TCD), in hematopoietic stem cell transplantation, 739 T-cell vaccines, against HIV, 831 T-cells activation of, by antigen-presenting cells, 801 function defect of, and live vaccines, 795 T-helper cell subsets, 33f Takayasu's arteritis, and fever of unknown origin, 614 Talaromyces, 1681t Talaromyces marneffei, 1698-1699 clinical manifestations of, 1699, 1699f diagnostic microbiology of, 1699, 1699f epidemiology of, 1698 management of, 1699 nature of, 1698 pathogenicity of, 1698-1699 Tanapox, 666 Tannerella forsythensis, 319 Tap deficiency, 719 Tapeworms. see Cestodes. Targeted metagenomic sequencing, 69-70 tat protein, 1485 tax protein, 1484f, 1491 Taxono-genomics, 65-66 Teacher, and occupational infections, 648t-649t Tedizolid, 1230 Tegument, 1763 Teichoic acids, 1512, 1516 Teicoplanin, 1191, 1254, 1254t for anaerobic bacteria, 1643 mode of action of, 1164 pharmacodynamics of, 1167 Telaprevir (TVR), for hepatitis C, 1331 Telavancin, 1252-1253, 1254t mode of action of, 1164 resistance to, 1164-1167 Telbivudine (LDT), for chronic hepatitis B, 1329 Temporal classifications, in osteomyelitis, 390 Temporal lobe, brain abscess, 199 Tendinitis, in quinolones adverse effects, 1247 Tenofovir, 1148t, 1300 adverse reactions of, 1300 antiretroviral drugs, 920-921 chemical structure of, 1296f description of, 1300 dosage of, 1300 in special circumstances, 1297t, 1300 drug interactions of, 1300 effect on oral contraceptives, 907t for hepatitis B virus (HBV), in HIV, 896-897 for HIV, 825-826 indications of, 1300 in occupational exposure, to HIV infection, 835 perinatal HIV transmission prevention, 909t pharmacokinetics and distribution of, 1300 and renal function, 921 resistance of, 1300 route of administration, 1300 Tenofovir alafenamide (TAF), for chronic hepatitis B, 1329 Tenofovir disoproxil fumarate (TDF), for chronic hepatitis Terconazole, for vulvovaginal candidiasis, 488t Testing algorithm, in HIV diagnosis, 1487, 1488f Tetanospasmin (TS), 208 Telithromycin (Continued) for tularemia, 1089, 1617 Tetraparvovirus, 1449 Th17 cells, 801 Thailand (THAI) virus, 1502t Thalassemias clinical features of, 1056-1057, 1057f pathogenesis and pathology of, 1054-1055 \u03b1-Thalassemias, 1054 \u03b2-Thalassemias, 1054 Thalidomide, 960, 1379 Theory of reasoned action, and HIV, 826 Therapeutic drug monitoring (TDM), 916, 1153 Therapeutics, disease prevention and control, 57-58 Thermal injury, 698 immune system response to, 698, 699t Thermometry, clinical, 606 Thermonuclease, 1513t-1514t Thermoregulation, 606-607, 607f acute-phase response, 608-609 endogenous antipyretics, 609 Theta toxin, 1633 Thiabendazole, 1352t-1362t, 1372 for gastrointestinal helminth, 1000-1001, 1001t Thiacetazone, as antituberculosis agent, 1271 Thiamphenicol, 1173 bacterial targeting, 1173 chemical structure of, 1173 mode of action of, 1173 pharmacodynamics of, 1173 resistance to, 1173 Thioamides, as antituberculosis agent, 1270 Thoracic infection, anaerobic bacteria in, 1632f Thoracic lymphadenopathy, 145 Thoracic surgery, for pleural effusion, 304 Thoracoscopy, tuberculosis, 279-280 Thottapalayam (TMP) virus, 1502t Throat swabs, for diphtheria, 1544 Thumb sign, in epiglottitis, 232-233, 233f Thymoma, 809, 810t Thyroiditis subacute, and fever of unknown origin, 614 suppurative. see Suppurative thyroiditis TIBOLA-DEBONEL-SENLAT, 1667t Ticarcillin for anaerobic bacteria, 1210, 1643 antimicrobial spectrum, routes of administration and dosages, 1206t-1207t dosage in renal failure, 1213t-1214t drug interactions, 1216 for lung abscess, 269f for P. aeruginosa infection, 1210 susceptibilities of selected bacteria to, 1208t-1209t Ticarcillin-clavulanate for complicated urinary tract infection, 545t for cystic fibrosis, 301 dosage in renal failure, 1213t-1214t for lung abscess, 269f pharmacokinetics of, 1205t susceptibilities of selected bacteria to, 1208t-1209t Ticarcillin-clavulanic acid for Alcaligenes spp., 1597 antimicrobial spectrum, routes of administration and dosages, 1206t-1207t for Stenotrophomonas maltophilia, 1597 Tick bite, infections from, 191t 651t and recreational infections, 644 vaccination, for travelers, 950 Tick-borne encephalitis virus, encephalitis/myelitis caused by, 192t Tick-borne lymphadenopathy, 1092t-1093t Tick-borne relapsing fever, 1105, 1105t, 1109 Tick-borne rickettsiae, and recreational infections, 644 Tick-borne rickettsial infections, and occupational infections, 648t-649t Ticks arboviruses, 1493, 1495t relapsing fever from, 1607-1608 topical rickettsioses and, 1091, 1092t-1093t tularemia and, 1086, 1087f Tigecycline for anaerobic bacteria, 1643 background in, 1256 against carbapenamase-resistant gram-negative bacilli, 1290t chemical structure of, 1168 for chronic obstructive pulmonary disease, 1259 distribution of, 1257 resistance to, 1169, 1257 route of administration of, 1258 for Stenotrophomonas maltophilia, 1597 structure of, 1257f Tinea barbae, clinical features of, 124, 124f see Tissue biopsy damage induced by micro-organisms, 18, 18t see also specific tissues Tissue amebicides, 1012 Tissue biopsy, for laboratory diagnosis, of mycobacteria, 1651-1652, 1651t Tissue culture vaccines, side effects of, 1463 Tissue factor pathway inhibitor (TFPI), 423 Tissue-helminth infections, eosinophilia and, 985 Tissue protozoa, 1751-1762 Tissue specimen collection, 1634t for helminths diagnosis, 1776 TLRs. see Toll-like receptors (TLRs). TMP-SMX. see Trimethoprim-sulfamethoxazole (TMP-SMX). TNF receptor-associated periodic syndrome (TRAPS), 614 Tobramycin clinical use of, 1234 for complicated urinary tract infection, 545t for conjunctivitis, 152 for cystic fibrosis, 301 for hospital-acquired pneumonia, 260t pharmacokinetic parameters for, 1234t resistance, 1185-1186 Tocilizumab, 798t-799t, 801 Tocolytic therapy, malaria in pregnancy, 1143t-1144t Toll-like receptors (TLRs), 27-30, 30t in rheumatic fever, 472 in sepsis, 421, 422t Tongue coating, halitosis, 319 Tonsillitis, anaerobic bacteria in, 1636t, 1637-1638 Topical antiseptics endophthalmitis prevention, 159-160 and surgical site infection prevention, 688-689 Topical therapies, for psoriasis, 880 Topografov (TOP)virus, 1502t Topoisomerase IV, 1174, 1176f, 1186 Topoisomerases, inhibition of, 1174 TORCH syndrome, 166 Torovirus, diarrhea and, 338 Toscana, 1495t Total dystrophic onychomycosis, 125, 125f Total parenteral nutrition, in intestinal transplant patients, 756 Tourette's syndrome, in rheumatic fever, 473-474 Toxic epidermal necrolysis, 88, 88f 'Toxic' follicular conjunctivitis, 981t Toxic shock syndrome (TSS) 508t diagnostic microbiology of, 1754 epidemiology of, 1753 in HIV, in low-and middle-income countries, 892 immunity of, 1753 lincosamide, 1226 lymphadenopathy, 142 management of, 1755-1756 in myocarditis, 448 nature of, 1753 opportunistic infection in HIV of, 856-857 pathogenicity of, 1753 prevention of, 1753-1754, 1753b transmission of, 665t, 807 treatment of, 1345t-1351t Toxoplasma titer difficulties in interpretation of serologic results of, 517, 518t history and examination of mother in, 518 investigation of, 517-518 management of, 518-519 other considerations in, 519 pathogenesis of, 517 serologic studies in mother, 518 treatment of, 518-519 eye involvement in, 982 and fever of unknown origin, 613 in hematopoietic stem cell transplantation, 743t, 745f in HIV/AIDS, 856-857, 857f in low-and middle-income countries, 892 primary prophylaxis for, 857 immunity, 1753 in the immunocompromised host, 1755, 1755f in kidney transplant patients, 768-769 lymphadenopathy and, 137t-138t management of, 1755-1756 nature of, 1753 pathogenicity of, 1753 prevention of, 1753-1754, 1753b prophylaxis in HIV-infected patients, 914 in HIV-infected pregnant women, 910 secondary prevention of, 1755-1756 in thoracic transplantation patients, 747t in transfusion-related infections, 704t treatment of, 1345t-1351t uveitis and, 166, 175-176 Tracheal colonization factor (TCF-A), 1613t Tracheal cytotoxin (TCT), 1612, 1613t Tracheobronchitis, in thoracic transplantation patients, 749 Trachipleistophora anthropophthera, in systemic microsporidiosis, 1741 Trachipleistophora spp., 1741 Trachoma, 151, 979-981, 1678 Traditional pricing model, 1384 Trans-theoretical model of change, in HIV, 826 Transaminase in hepatitis A virus, 364 in hepatitis C virus, 369-370, 369f in hepatitis E virus, 372 Transcytosis, 15 Transesophageal (TEE) echocardiography, for infectious endocarditis, 611 Transferrin-binding proteins, 1557t, 1559 Transfusion-related infections, 701-704 blood products as, bacterial contamination of, 702-703, 704t Creutzfeldt-Jakob disease (CJD) and, 704 parasites in, 703-704, 704t risk of, 701t reducing, methods for, 702t viral pathogens in, 701-702, 703t Transmissible mink encephalopathy, 215t Transmissible spongiform encephalopathies (TSE), 214-220 clinical features of, 217, 218f development of therapies for, 220 epidemiology of, 214-215 molecular strain typing of, 217-219 pathogenesis and pathology of, 217-220, 219f prevention of, 220 Transmission based precautions, 58-60, 59b-60b dynamic, 50 see also specific infections 'Transplant tourism' , 806 Transplantation in antibiotic prophylaxis, 1157t-1158t bone marrow, Bk polyomavirus in, 1447 brain abscess and, 199 kidney, BK virus nephropathy in, 1447, 1447f Transportation, of specimens, 1634-1635 Transposons, 1195 carrying resistance genes, structure of, 1195f Transthoracic (TTE) echocardiography, for infectious endocarditis, 611 Transtracheal aspiration, lower respiratory tract infections, 268 Trauma, 586t-587t brain abscess and, 199 infections following, 684-692 antibiotic therapy principles for, 691 environment-derived risk factors, 686 pathogenesis of inflammation and organ dysfunction, 684-686, 685f postoperative period, 688-691 treatment-derived risk factors, 686 mycetoma and, 1714 subdural empyema/intracranial epidural abscess, 205t Travel, and emerging infectious diseases, 43 Travel history, and fever of unknown origin, 615 Travelers approach to eosinophilia in, from tropics, 984-988 behavioral factors of, 952 burden of disease, 941-942 diarrhea. see Travelers' diarrhea (TD) environmental hazards in, 951-952 jaundice in, 1134-1136, 1135t lymphadenopathy, splenomegaly and anemia, 1139-1140, 1140b other diseases and considerations in, 952 post-travel illness in, 952 and recreational infections, 643, 643t sexually transmitted diseases in, 952 sexually transmitted infection in, 1137-1138 sources of information and, 952 Travelers' diarrhea (TD), 332, 332f, 375-376, 950, 1727 Treatment-derived risk factors, infection following surgery and trauma, 686 Trematoda, nature of, 1763 Trematodes, 989t, 1764t blood. see Blood flukes clinical manifestations of, 1778 description of, 1032 epidemiology of, 1765-1766 importance of physical environment in, 990 infections of, 1032, 1036-1037 intestinal. see Intestinal flukes liver. see Liver flukes lung. see Lung flukes pathogenesis and pathology of, 993-994 pathogenicity of, 1770-1772 prevention of, 1772 treatment of, 1001t see also specific genera Trench fever, 1674 Treponema, 1600 in lymph node enlargement, 147t-148t Treponema denticola, 319 Treponema pallidum, 559, 961 causing retinitis and uveitis, 169t, 171t in chronic meningitis, 186t in congenital infection clinical features of, 510 diagnosis of, 512, 512t management of, 513 pathogenesis and pathology of, 506-507 screening for, during pregnancy, 508t diagnosis of, 563-564 encephalitis/myelitis caused by, 193t-194t etiology of, 1138t jaundice, 1135t in liver transplant patients, 751 macrolides, 1221 pathogenesis and pathology of, 559-560 uveitis and, 168-169 Treponemal antibody tests, 564, 564t Treponemal infections, 962t Treponematoses, endemic, 961-965 Trimethoprim-sulfamethoxazole plus gentamicin, indication, meningitis, 187t Trimethylamine, 483-484 Trimetrexate, 1352t-1362t, 1365 Trismus, lateral pharyngeal space infection, 314 Trombiculid mites, 105, 1670 scrub typhus and, 1091 Tropical pulmonary eosinophilia, 1049 treatment of, 1345t-1351t Tropical rickettsioses, 1091-1097, 1092t-1093t Tropical spastic paresis, 1491 Tropical sprue, chronic diarrhea, 349 'Tropism' , 15 Troponin T, 448 Trueperella, 1548t Trypanosoma brucei antigenic variations in, 25 epidemiology of, 1761 lymphadenopathy, 142 nature of, 1761 pathogenicity of, 1761f Trypanosoma brucei gambiense, 1761 African trypanosomiasis, 966, 967f clinical features of, 968, 968f epidemiology of, 967t management of, 969t, 1345t-1351t prevention of, 967 Trypanosoma brucei rhodesiense, 1761 Trypanosoma cruzi, 109, 1065, 1758 in HIV in low-and middle-income countries, 892 life cycle of, 1065-1066, 1067f in liver transplant patients, 751 in myocarditis, 447 transmission of, 807, 1065-1066, 1068f treatment of, 1345t-1351t Trypanosoma rangeli, 1762 Trypanosomiasis, 119, 1758, 1758t African. see African trypanosomiasis American. see Chagas disease dermatologic manifestations of, 114t-115t in HIV in low-and middle-income countries, 892 treatment of, 1345t-1351t Tsetse flies, 106t, 111-112, 112f infections from, 191t Tsukamurella, 1550t, 1552 Tsutsugamushi triangle, 1670, 1670f Tuberculids, 118 Tuberculin skin test (TST), 274-275, 802, 1657, 1658t in HIV infection, 913 Trimethoprim-sulfamethoxazole (TMP-SMX) (Continued) pulmonary, 276-277 in breast-feeding, 516 corticosteroids for, 306 screening for, before biologic therapy, 802 second stage-adaptive immunity to, 273 spread of infection of, 271-272 surgery for, 284 in thoracic transplantation patients, 749 transmission, in closed institutions, 271-272 and tumor necrosis factor inhibitor, 799 of urogenital tract. see Urogenital tract tuberculosis vaccination, for travelers, 950 vaccines, 275 worldwide incidence and prevalence, 271, 272f Tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS), 859-860, 861f-862f, 862 common and important manifestations of, 861b corticosteroid therapy for, 864 Tuberculosis cutis orificalis, 117 Tuberculosis verrucosa cutis, 117 Tuberculous lymphadenitis, of axilla, 140f Tuberculous meningitis, 186-187 Tuberculous pericarditis, 450, 454 corticosteroids for, 480 Tuberculous peritonitis, 359-360 Tubo-ovarian abscesses, 493-494 Tubulinosema acridophagus, 1741 Tula (TUL) virus, 1502t Tularemia, 1085-1090 Tumor necrosis factor (TNF) inhibitors, infectious risk associated with, 797-800 bacterial infections, 797-799 fungal infections, 799-800 mycobacterial infections, 799 protozoa, 800 viral infections, 800 Tumors solid, 723 see also Cancer; Neoplasia; specific tumors Tunga penetrans, 108 Two-stage exchange, in surgery, for prosthetic joint infection (PJI), 402 Tympanostomy tubes, otitis media, 237 Typhlitis, in cancer patients, 727-728 Typhoid diseases, vaccination for travelers, 949 Typhoid fever, 1002-1007, 1574 acute shedding and chronic carriage and, 1004-1005 quinolones for, 1245 severe, 1004, 1006-1007 Typhoid rose spots, 1004f Typhoidal tularemia, 1089 Typhus epidemic. see Epidemic typhus eye involvement in, 982 jaundice and, 1136 murine. see Murine typhus and occupational infections, 648t-649t scrub. see Scrub typhus Typhus group (TG), 1091 Typhus group rickettsiae, 1669-1670 dosage of, 1313-1314 in special circumstances, 1314, 1314t indications of, 1314 cytomegalovirus, 1314 cytomegalovirus retinitis, 1314t in intestinal transplant patients, 758-759 for kidney transplant patients, 766 mechanism of action, 1313 pharmacokinetics and distribution of, 1313 prophylaxis with in cytomegalovirus, 1314 in liver transplant patients, 754t, 755 resistance to, 1315 route of administration, 1313-1314 in vitro activity, 1313 'Vallecula sign,' in epiglottitis, 232-233 Valproate, 476 Valve culture, in endocarditis, 461 Valve lesions, degenerative, 457-458 Valve surgery, 476 van genes, 1191 VanA-type resistance, to glycopeptides, 1191, 1192f Vancomycin, 1191, 1249-1252 adverse reactions and interactions of, 1252 for anaerobic bacteria, 1643 for Bacillus cereus, 1542 for cancer patients, 735 for catheter-related bloodstream infection (CRBSI), 436t cellulitis and, 92 for coagulase-negative staphylococcal infections, 1521-1522 discovery of, 1217 distributions of, 1249-1250, 1250t dosage of, 1250 in special circumstances, 1251-1252, 1254t for foot ulcers, 131t skin and soft tissue, 1251 for infective arthritis, 386t for intra-abdominal sepsis, 357-358 \u03b2-lactam resistance, 1292 mode of action of, 1164 monitoring of, 1251 in outpatient parenteral antimicrobial therapy, 1201 pharmacodynamics of, 1167, 1250, 1251t pharmacokinetics of, 1249-1250, 1251t for pneumococcal infections, 1209 prophylaxis with, 159, 1158t and surgical site infections, 687 resistance to, Erysipelothrix rhusiopathiae, 1542 route of administration of, 1250 for Staphylococcus aureus, 1520 Vancomycin-intermediate Staphylococcus aureus (VISA), 468, 1192, 1249, 1249t Vancomycin-resistant enterococci (VRE), 1249, 1249t epidemiology of, 1526-1527, 1528f resistance, 1191 Vancomycin-resistant staphylococci, 467-468 Vancomycin-resistant Staphylococcus aureus (VRSA), 1249, 1249t, 1519 VanX protein, 1191 VanY protein, 1191 Variant Creutzfeldt-Jakob disease (vCJD), 215t myelitis caused by, 192t epithelial keratitis, 154 in hematopoietic stem cell transplantation, 741-742 in HIV/AIDS, 881-882, 883f hyperimmune globulin, 1433 in immunosuppressed patients, 1432 in kidney transplant patients, 766 management of, 76 and natalizumab, 802 opportunistic infection in HIV of, 853 pathogenicity of, molecular and cellular basis of, 1431 in pregnancy, 499t reactivation of, in liver transplant patients, 753 in thoracic transplantation patients, 748 vaccine, Oka-derived strain of, 1432 Variola virus, 75t and bioterrorism, 671t Vascular access, outpatient parenteral antimicrobial therapy, 1201 Vascular cell adhesion molecule 1 (VCAM-1), 1017 Vascular surgery, antibiotic prophylaxis and, 1157t-1158t, Venezuelan equine encephalitis, 1495t Venezuelan equine encephalitis virus, 193t-194t Venous stasis, chronic, 90, 91f Ventilator-associated pneumonia (VAP), 60, 258-262, 259t, 1375 and burn infections, 698 community-acquired pneumonia and, 254 incidence of, 690-691, 690t Pseudomonas aeruginosa in, 1587 Ventriculoatrial shunts, 221f Ventriculoencephalitis, cytomegalovirus, 853 Ventriculoperitoneal shunts, 221f Vernal catarrh, 981t Vero/SLAM cell line, 1399 Verruga peruana, 113 VersaTrek\u00ae, for mycobacteria, 1653 Vertebral osteomyelitis, 391-392, 392f, 1589 Vesicoureteral reflux, in pyelonephritis, 548 Vesiculobullous exanthems, 75t Vesivirus nature of, 1393 taxonomy of, 1394t Vestibular abscess, 313, 313f Vestibular toxicity, of aminoglycosides, 1235t, 1236 Veterinarians, and occupational infections, 648t-649t Vibrio alginolyticus, 337, 1607 Vibrio cholerae, 1604-1607 and bioterrorism, 671t characteristics of, in food-borne diarrheal illness, 330t clinical features of, 1606-1607 diagnostic microbiology of, 1606 diarrhea and, 337, 339 doses of, in diarrheal illness, 329t El Tor, 337 epidemiology of, 1604-1605 management of, 1607 microbiology of, 1604 pathogenesis of, 1605 prevention of, 1605-1606 spread of, 944 variant O139, 1604-1605 Vibrio cholerae non-O1, 337 Vibrio cholerae O1, 337 Vibrio cholerae O139, 337 Vibrio cholerae O139 (Bengal), 337 Vibrio damselae, 1607 Vibrio fluvialis, 337, 1607 Vibrio furnisii, 337 Vibrio hollisae, 1607 Vibrio mimicus, 337, 1607 Vibrio parahaemolyticus, 1607 characteristics of, in food-borne diarrheal illness, 330t diarrhea, 337 Vibrio PI (VPI), 1605 Vibrio vulnificus, 337, 662, 1607 cellulitis and, 91 and occupational infections, 648t-649t Video-assisted thoracic surgery (VATS), for pleural effusion, 304, 305f Vincent's angina, 316 anaerobic bacteria in, 1636 Vincent's disease, 316, 316f Vincent's infection, 316 Vincristine, immunosuppression and, 1380t Viomycin, as antituberculosis agent, 1270 Viral arthritis, 385-386, 387t Viral budding, 1486 Viral culture, in genital herpes, 572 Viral encephalitides, and bioterrorism, 672t Viral enteritis, 338 Viral exanthems, 75-83, 75t classic, 75-79 nonclassic, 79-83 see also specific viral exanthems Viral hemorrhagic fevers (VHF), 75t, 80, 1110-1118 and bioterrorism, 671t-673t, 678 diagnosis and clinical features of, 1113-1117, 1114t-1116t, 1116f epidemiology of, 1112t with hepatic involvement, 378-379 management of, 1117, 1117t pathogenesis of, 1113 prevention of, 1117-1118 in travelers, 952 virology of, 1110, 1111f Viral hepatitis dosage regimens in, 1328t drugs to treat, 1327-1332 Virions, 5, 7f Virulence factors identification, genome sequencing, 66 'Virulence' genes, 12 Virulent mycobacteria, 273 Viruria, BK polyomavirus, 1447 Virus-induced cytopathic effect, 19-21, 21f Virus isolation, influenza viruses, 1469-1470 Virus-like particles, 832 travelers' diarrhea and, 950 viral gene expression strategies, 8 Visceral larva migrans, treatment of, 1345t-1351t Visceral leishmaniasis, 1757, 1757f amphotericin B for, 1364 clinical features of, 1060-1062, 1061f, 1061t dermatologic manifestations of, 119 epidemiology of, 1059 and fever of unknown origin, 613 in HIV in low-and middle-income countries, 892 lymphadenopathy and, 137t-138t monitoring response to treatment for, 1064 post-kala-azar dermal, 1062 spread of, 945 Visual inspection with acetic acid (VIA), 582, 582f Vitamin A, deficiency, keratitis, 152 Vitamin D, for bone health, 929 Vitiligo, 586t-587t Vitrectomy, endophthalmitis, 162 Vitreous specimens, endophthalmitis, 161-162 Vittaforma corneae, 1741 Volatile fatty acids, of anaerobic bacteria, 1633 drug interactions of, 1339-1340 for endophthalmitis, 162-163 for esophageal candidiasis, 1686 for fusariosis, 1700 for histoplasmosis, 294 indications of, 1339 for mycetoma, 1723 for oropharyngeal candidiasis, 1684 for paracoccidioidomycosis, 297 pharmacodynamics of, 1339 pharmacokinetics and distribution of, 1339 route of administration, 1339 for sporotrichosis, 298 for Talaromyces marneffei, 1699 in thoracic transplantation patients, 750 Vulva, rhinosporidiosis in, 1721 Vulvar cancer, human papillomavirus and, 579 Vulvitis, 489-490, 526 Vulvovaginal candidiasis (VVC), 486-489, 1686 systemic agents for, 488-489 topical agents for, 488, 488t Vulvovaginitis, from Candida, 1684",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": [
        {
            "text": " 276-277 clinical presentation of, 276-277, 276f-277f complications of, 277 dermatologic manifestations, 114t-115t, 116-118 diagnosis of, 279-280 drug-resistant, 283-284, 872, 1273-1274 endobronchial, 276 in low-and middle-income countries, 891 due to Mycobacterium bovis, 664 epidemiology of, 271-272, 272f, 1647-1648 extrapulmonary, 773, 869 abdominal infection, 279 Zanamivir (Continued) ",
            "cite_spans": [
                {
                    "start": 1,
                    "end": 204,
                    "text": "276-277 clinical presentation of, 276-277, 276f-277f complications of, 277 dermatologic manifestations, 114t-115t, 116-118 diagnosis of, 279-280 drug-resistant, 283-284, 872, 1273-1274 endobronchial, 276",
                    "ref_id": null
                },
                {
                    "start": 294,
                    "end": 343,
                    "text": "271-272, 272f, 1647-1648 extrapulmonary, 773, 869",
                    "ref_id": null
                },
                {
                    "start": 369,
                    "end": 390,
                    "text": "Zanamivir (Continued)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "annex"
        }
    ]
}